{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:39Z","timestamp":1784557059034,"version":"3.55.0"},"reference-count":9,"publisher":"Bioscientifica","content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10,6]]},"abstract":"Summary<\/jats:title>\n Tumor-induced osteomalacia (TIO) is caused by the hormone fibroblast growth factor 23 (FGF-23). It is mainly produced in the tissue of mesenchymal tumors. Patients with TIO frequently suffer from a chronic decompensated pain syndrome and\/or muscle weakness with postural deformity. Despite the severity of the disease, the diagnosis is frequently established late. In some cases, it takes several years to establish the condition. This case report concerning a 68-year old woman demonstrates the selective blood sampling for FGF-23 as path-breaking diagnostics to confirm the diagnosis of a neuroendocrine tumor.<\/jats:p>\n \n Learning points:<\/jats:title>\n \n \n Tumor-induced osteomalacia is a rare condition compared to other paraneoplastic syndromes.<\/jats:p>\n <\/jats:list-item>\n \n It causes complex symptoms such as progressive reduction of physical capacity, exhaustion, fatigue, a decompensated pain syndrome of the musculoskeletal system and fractures of several bones.<\/jats:p>\n <\/jats:list-item>\n \n Elevated serum levels of FGF-23 implicate massive phosphate elimination and resulting hypophosphatemia.<\/jats:p>\n <\/jats:list-item>\n \n The diagnosis is often established over a period of several years because the localization of small FGF-23-producing tumors is complicated.<\/jats:p>\n <\/jats:list-item>\n \n It is the combination of MRI and selective blood sampling for FGF-23 which permits reliable identification of tumors causing TIO and leads to accurate localization.<\/jats:p>\n <\/jats:list-item>\n \n \n In a patient with generalized pain and reduced physical capacity, osteological parameters such as phosphate, 25-OH vitamin D\n 3<\/jats:sub>\n and 1,25-(OH)\n 2<\/jats:sub>\n D\n 3<\/jats:sub>\n , as well as bone-specific alkaline phosphatase levels in serum should be determined. Hypophosphatemia should always lead to further diagnostic investigations aiming at the detection of an FGF-23-producing tumor.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>","DOI":"10.1530\/edm-17-0006","type":"journal-article","created":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T02:28:30Z","timestamp":1507256910000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":1,"title":["Selective blood sampling for FGF-23 in tumor-induced osteomalacia"],"prefix":"10.1530","volume":"2017","author":[{"given":"Hans-Christof","family":"Schober","sequence":"first","affiliation":[{"name":"1Departments of Internal Medicine"},{"name":"2Endocrinology, Rheumatology\/Immunology, Klinikum S\u00fcdstadt Rostock, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kneitz","sequence":"additional","affiliation":[{"name":"2Endocrinology, Rheumatology\/Immunology, Klinikum S\u00fcdstadt Rostock, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Fieber","sequence":"additional","affiliation":[{"name":"2Endocrinology, Rheumatology\/Immunology, Klinikum S\u00fcdstadt Rostock, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Hesse","sequence":"additional","affiliation":[{"name":"1Departments of Internal Medicine"},{"name":"2Endocrinology, Rheumatology\/Immunology, Klinikum S\u00fcdstadt Rostock, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Schroeder","sequence":"additional","affiliation":[{"name":"3Department of Neurosurgery, Universit\u00e4tsmedizin Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"key20171025115953859_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1507\/endocrj.48.603","article-title":"Fibroblast growth factor (FGF)-23 and hypophosphatemic rickets\/osteomalacia","volume":"48","author":"Fukomoto","year":"2001","journal-title":"Endocrine Journal"},{"key":"key20171025115953859_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","article-title":"Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and comprehensive review of literature","volume":"28","author":"Folpe","year":"2004","journal-title":"American Journal of Surgical Pathology"},{"key":"key20171025115953859_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0049-0172(95)80016-6","article-title":"Tumor-induced osteomalacia","volume":"25","author":"Schapira","year":"1995","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"key20171025115953859_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","article-title":"Localisation of mesenchymal tumours by somatostatin receptor imaging","volume":"359","author":"Jane de Beur","year":"2002","journal-title":"Lancet"},{"key":"key20171025115953859_bib5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.bone.2004.06.014","article-title":"Bone as a source of FGF-23: regulation by phosphate?","volume":"35","author":"Mirams","year":"2004","journal-title":"Bone"},{"key":"key20171025115953859_bib6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2005.01.001","article-title":"Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET\/CT scan for the diagnosis and follow up in one case","volume":"36","author":"Dupond","year":"2005","journal-title":"Bone"},{"key":"key20171025115953859_bib7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jbmr.316","article-title":"Selective venous catheterization for the localization of phosphaturic mesenchymal tumors","volume":"26","author":"Andreopoulou","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"key20171025115953859_bib8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2169\/internalmedicine.47.0761","article-title":"Development of tumor-induced osteomalacia in subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23","volume":"47","author":"Ogura","year":"2008","journal-title":"Internal Medicine"},{"key":"key20171025115953859_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1227\/NEU.0b013e31821867f7","article-title":"Osteomalacia caused by skull base tumors: report of 2 cases","volume":"69","author":"Uno","year":"2011","journal-title":"Neursurgery"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2017\/1\/EDM17-0006.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2017\/1\/EDM17-0006.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:31Z","timestamp":1784555191000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,6]]},"references-count":9,"URL":"https:\/\/doi.org\/10.1530\/edm-17-0006","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,6]]}}}